Intercept's Fibrosis Success Gives Galectin High Hope

Intercept Pharmaceuticals served as a catalyst for biotechnology firms in the fibrosis space on January 9. That's when the company said that its Phase 2 trial of obeticholic acid for the treatment of nonalcoholic steatohepatitis was being stopped early after a Data Safety Monitoring Board determined the drug candidate had already met its primary ... (more)

http://ift.tt/1gn57oY